AV-GBM-1 showed early promise in an interim overall survival (OS) analysis of an ongoing phase II trial in patients with newly diagnosed glioblastoma, according to Aivita Biomedical, Inc., the company developing the immunotherapy.
Kazia anticipates reporting additional data later this year and final results in the first half of next year. Beyond this phase II study 4 other ongoing studies are exploring paxalisib in patients with different types of brain cancer.
- AIVITA Biomedical Provides Update of Ongoing Phase 2 Glioblastoma Trial from Year-End Survival Analysis. Published April 8, 2020. https://bwnews.pr/2xcaF5e. Accessed April 8, 2020.
- Kazia's Paxalisib Shows Positive Overall Survival Signal in Phase II Glioblastoma Study. Published April 7, 2020. https://yhoo.it/2JP8QOA. Accessed April 7, 2020.
... to read the full story